Pharmacokinetic and pharmacodynamic issues in respiratory infections Source: Annual Congress 2013 –PG9 How to optimise antibiotic use in respiratory infections Year: 2013
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008
Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019
Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003
Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019 Year: 2020
Serum pharmacokinetics of antituberculosis drugs in volunteers Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018 Year: 2019
Pharmacokinetic studies for the estimation of bioequivalence of two DPIs containing budesonide and formoterol Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Contamination and carry-over in clinical pharmacokinetic trials with aerosolized budesonide Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Antibiotics in critical care: dosing, therapeutic drug monitoring and continuous infusions Source: Eur Respir Monogr 2017; 75: 44-56 Year: 2017
Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Source: Eur Respir J, 54 (5) 1901508; 10.1183/13993003.01508-2019 Year: 2019
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Source: Eur Respir J, 54 (5) 1901806; 10.1183/13993003.01806-2019 Year: 2019
Bronchopulmonary pharmacokinetic (PK) profile of moxifloxacin in older adults undergoing diagnostic bronchoscopy Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002